Drake C T, Terman G W, Simmons M L, Milner T A, Kunkel D D, Schwartzkroin P A, Chavkin C
Department of Pharmacology, University of Washington, Seattle 98195.
J Neurosci. 1994 Jun;14(6):3736-50. doi: 10.1523/JNEUROSCI.14-06-03736.1994.
The granule cell population response to perforant path stimulation decreased significantly within seconds following release of endogenous dynorphin from dentate granule cells. The depression was blocked by the opioid receptor antagonists naloxone and norbinaltorphimine, suggesting that the effect was mediated by dynorphin activation of kappa 1 type opioid receptors. Pharmacological application of dynorphin B in the molecular layer was effective at reducing excitatory synaptic transmission from the perforant path, but application in the hilus had no significant effect. These results suggest that endogenous dynorphin peptides may be released from a local source within the dentate molecular layer. By light microscopy, dynorphin-like immunoreactivity (dynorphin-LI) was primarily found in granule cell axons in the hilus and stratum lucidum with only a few scattered fibers evident in the molecular layer. At the extreme ventral pole of the hippocampus, a diffuse band of varicose processes was also seen in the molecular layer, but this band was not present in more dorsal sections similar to those used for the electrophysiological studies. Electron microscopic analysis of the molecular layer midway along the septotemporal axis revealed that dynorphin-LI was present in dense-core vesicles in both spiny dendrites and unmyelinated axons with the majority (74%) of the dynorphin-LI-containing dense-core vesicles found in dendrites. Neuronal processes containing dynorphin-LI were observed throughout the molecular layer. The results suggest that dynorphin release from granule cell processes in the molecular layer regulates excitatory inputs entering the hippocampus from cerebral cortex, thus potentially counteracting such excitation-induced phenomena as epileptogenesis or long-term potentiation.
在齿状颗粒细胞释放内源性强啡肽后的数秒内,颗粒细胞群体对穿通路径刺激的反应显著降低。这种抑制作用被阿片受体拮抗剂纳洛酮和去甲双氢吗啡酮阻断,表明该效应是由强啡肽激活κ1型阿片受体介导的。在分子层药理学应用强啡肽B可有效减少来自穿通路径的兴奋性突触传递,但在海马回应用则无显著效果。这些结果表明,内源性强啡肽肽可能从齿状分子层内的局部来源释放。通过光学显微镜观察,强啡肽样免疫反应性(dynorphin-LI)主要见于海马回和透明层的颗粒细胞轴突,分子层中仅有少数散在纤维可见。在海马体的极腹侧,分子层中也可见到一条弥漫的曲张突起带,但在与用于电生理研究的类似的更靠背侧的切片中不存在此带。沿海马体颞中轴对分子层进行电子显微镜分析显示,强啡肽-LI存在于棘状树突和无髓轴突的致密核心囊泡中,大部分(74%)含强啡肽-LI的致密核心囊泡见于树突中。在整个分子层均观察到含有强啡肽-LI的神经元突起。结果表明,分子层颗粒细胞突起释放的强啡肽调节从大脑皮质进入海马体的兴奋性输入,从而可能抵消诸如癫痫发生或长时程增强等兴奋诱导现象。